FDA Could Approve Psychedelic Drug This Summer
FDA fast-tracks three psychedelic drugs for approval by summer, potentially enabling treatment-resistant depression and PTSD medications to reach patients in months instead of years.
Objective Facts
On April 24, 2026, the FDA issued national priority vouchers to three companies studying psychedelic-based medicines: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. FDA Commissioner Marty Makary told NBC News the agency could potentially approve the first psychedelic drug by the end of summer using the priority voucher program. The vouchers shorten the FDA's review process from its standard 10 to 12 months to just one to two months. This action follows President Trump's April 18 executive order directing the FDA to prioritize psychedelic drugs with breakthrough therapy designation. The FDA also approved an early-phase clinical study of noribogaine hydrochloride, a derivative of ibogaine, for alcohol use disorder—the first time the agency has allowed a clinical study of an ibogaine derivative in the U.S.
Left-Leaning Perspective
The American Psychiatric Association, represented by CEO and medical director Dr. Marketa Wills, welcomed federal investment in psychedelic research but raised concerns that current scientific evidence is insufficient to support use of these therapies outside approved research settings, emphasizing that rigorous study, strong patient protections, and physician-led oversight remain essential. Mason Marks, a senior fellow on psychedelics law at Harvard Law School's Petrie-Flom Center, expressed explicit concern about White House pressure rushing treatments through approval, stating it would be problematic and could set back progress. Experts cited in neutral outlets caution that the faster timeline raises questions about safety oversight, long-term side effects, and whether regulators should move quickly when approving drugs that remain controversial. Critics of the priority voucher program noted it was implemented without Congressional input and could undermine FDA trust by allowing companies to make financial contributions to secure vouchers. Left-leaning outlets highlighted that Trump's order drew particular attention for including ibogaine, a naturally occurring psychoactive compound with long-standing safety concerns and cardiac risks flagged by Nora Volkow of the National Institute on Drug Abuse, which remains a major barrier to approval.
Right-Leaning Perspective
Bryan Hubbard, CEO of Americans for Ibogaine advocacy group, told The Hill that Trump 'seems to be someone who is open to innovation and is not imprisoned by dogmatic viewpoints'. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, argued in The Hill that Trump's administration lacks the political constraints Democratic administrations faced about appearing progressive, making it easier for this particular Republican administration to be bold on psychedelics—comparing it to Nixon going to China. Trump himself told The Hill he only recently learned about ibogaine from podcaster Joe Rogan, responding via text 'Sounds great. Do you want FDA approval? Let's do it,' and later pushed marijuana rescheduling forward after Rogan raised it publicly. According to STAT News, Trump told officials 'I called Bobby, I called Oz, I called Marty and Jay' for uniform support, and Mehmet Oz noted the executive order was written in less than a week, with Trump refusing to take no for an answer. However, Anne Schlafly Cori, chair of the conservative Eagle Forum, broke ranks, saying 'Trump is famous for not doing anything more than Diet Coke, so all I can think of is that he doesn't realize the dangers that he is unleashing', representing conservative skepticism about removing drug restrictions.
Deep Dive
The FDA on April 24, 2026, issued national priority vouchers to three companies studying psychedelic-based medicines following Trump's April 18 executive order to accelerate research. These vouchers reduce the standard FDA review timeline from 6-10 months to just 1-2 months, potentially enabling approval decisions by summer 2026. This reversal comes after the FDA rejected MDMA-assisted therapy for PTSD in 2024 despite political pressure, citing insufficient safety and efficacy evidence and concerns about poor study design. The policy generates genuine tension: ibogaine, one of the priority drugs, carries known cardiac risks that halted U.S. research in the 1990s, yet remains central to Trump's order partly due to Joe Rogan's advocacy and veteran testimonials. Even supporters like the American Psychiatric Association agree that rigorous, research-driven approaches with solid evidence and patient safety must remain priorities, yet the accelerated timeline inverts traditional scientific sequencing. The broader question is whether unilateral executive action via priority vouchers—implemented without Congressional input—represents responsive innovation or regulatory capture vulnerable to lobbying and White House pressure. What happens next matters enormously: if Phase 3 trials show strong safety and efficacy by summer, approval could genuinely help veterans and treatment-resistant patients; if trials are incomplete or concerning, approval could damage FDA credibility and undermine future psychedelic research. Outcomes will depend on whether Phase 3 trials confirm safety and efficacy—enabling rapid clinical access—or unresolved safety concerns, lack of DEA rescheduling, and insufficient clinician training stall real-world implementation.